Table 4.
Expected annual number of cervical screening examinations and colposcopies required for detecting ≥CIN 3 in the base case and 1-year follow-up scenario
| Strategy | Number of screening examinationsa,b | No. of colposcopies per ≥CIN 3 detected | |||
|---|---|---|---|---|---|
| Routine | Triage | Retest | Colposcopies | ||
| Base case | |||||
| Cytology (reflex HPV test for ASC-US) | 30,364 | 1,282 | 0 | 2,104 | 4.76 |
| HPV with genotyping (reflex cytology [ASC-US]) | 23,065 | 6,372 | 1,024 | 2,159 | 3.06 |
| HPV HR only (with reflex to cytology [ASC-US]) | 22,872 | 8,405 | 6,557 | 2,339 | 3.95 |
| Co-testing (with cytology and HPV testing) | 22,848 | 0 | 6,686 | 2,967 | 4.79 |
| 1-year follow-up scenario | |||||
| Cytology (reflex HPV test for ASC-US) | 30,294 | 1,282 | 0 | 2,104 | 4.76 |
| HPV with genotyping (reflex cytology [ASC-US]) | 23,201 | 6,265 | 1,021 | 2,130 | 2.73 |
| HPV HR only (with reflex to cytology [ASC-US]) | 23,201 | 8,079 | 6,332 | 2,249 | 2.89 |
| Co-testing (with cytology and HPV testing) | 23,161 | 0 | 6,479 | 2,915 | 3.67 |
ASC-US atypical squamous cells of undetermined significance, CIN cervical intraepithelial neoplasia, HPV human papillomavirus, HPV HR human papillomavirus, high-risk
aPer 100,000 women and annualized over a 40-year time horizon
bTriage tests included HPV test for Cytology and cytology for both HPV with genotyping and HPV HR only